The effect of a pill inserter on vaginal misoprostol dosing

Politz, L. B.; Chez, Ronald A.; Parsons, Michael T.; Huffman, K.

doi:10.1080/jmf.10.5.332.334-18

J Matern Fetal Neonatal Med

2001

DOI: 10.1080/jmf.10.5.332.334-18

|View full text |Cite

The effect of a pill inserter on vaginal misoprostol dosing

L. B. Politz

Ronald A. Chez

Michael T. Parsons

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2006

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Vaginal Misoprostol Administration for Cervical Ripening and Labor Induction

Gaffaney¹

2006

Clinical Obstetrics and Gynecology

View full text Add to dashboard Cite

Intravaginal misoprostol has been shown to be an effective agent for cervical ripening and induction of labor. Vaginal application of misoprostol has been reported in over 9000 women worldwide and seems to have safety profile similar to that of endocervically and intravaginally administered dinoprostone. Concern arises with the use of higher doses of intravaginal misoprostol (50 mcg or more) and the association with uterine contractile abnormalities and for this reason, use of low-dose misoprostol regimen has been recommended by the American College of Obstetricians and Gynecologists. The recommendation is use of a 25-mcg dose of misoprostol inserted into the posterior vaginal fornix and repeated every 3 to 6 hours as needed. Misoprostol administration to women with prior cesarean births seems to increase the likelihood of uterine scar disruption and should not be used in these women. There are reports of uterine rupture in women with unscarred uteri treated with vaginally applied misoprostol. Therefore, all patients need to be monitored adequately after misoprostol administration. Although there is a growing body of data regarding the ambulatory use of intravaginal misoprostol for cervical ripening, its use for this purpose cannot be recommended outside of investigational protocols at this time because of concerns for maternal and neonatal safety.

show abstract

Vaginal Misoprostol Administration for Cervical Ripening and Labor Induction

Gaffaney¹

2006

Clinical Obstetrics and Gynecology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The effect of a pill inserter on vaginal misoprostol dosing

Cited by 1 publication

References 7 publications

Vaginal Misoprostol Administration for Cervical Ripening and Labor Induction

Vaginal Misoprostol Administration for Cervical Ripening and Labor Induction

Contact Info

Product

Resources

About